ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers much earlier in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intramuscular injection of adrenaline for the treatment of acute life-threatening allergic reactions including Anaphylaxis. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.

ALK-Abelló A/S

ALK Suomi

ALK Norge

ALK Sverige

At ALK, we go to work every day to make a difference for the many people with allergies around the world. It is our ambition to make life with allergy surprisingly simple for as many people as possible, and we build upon our strong heritage as a pioneer in allergy immunotherapy, when we continue to innovate, develop and market new products and solutions to help improve the health of people with allergies. 

Every day, our employees contribute to our aspiration of becoming the world leader in allergy by coming to work to do their best in the pursuit of providing new and better allergy treatments and solutions. We work in a high-energy, international setting where it is imperative that our people thrive and develop. Creativity, influence and opportunities are key elements in developing our people. 

ALK is a global company with production sites in Denmark, France, Spain and the United States. ALK was founded in Copenhagen in 1923 and today we employ around 2,800 people around the world. Our global headquarters is located in beautiful surroundings in Hørsholm, north of Copenhagen.

Read more about ALK at www.alk.net

DBV Technologies

Science is the backbone of our culture and paramount for our ability to help people with allergy. We have been pioneering within respiratory allergy for over 100 years thanks to continued dedication from our employees, including our scientists who play a crucial role in research and development. 

One of our many dedicated scientists is Christian Uggerhøj Wøhlk, Associate Director of Immunology in Translational Research, who recently joined ALK after finishing his PhD research project within allergy immunotherapy and allergic asthma at Bispebjerg Hospital.  

Being able to join ALK's research team provided Christian with a line of professional possibilities and was a perfect continuation of his PhD work: 

"With ALK's extensive experience within several immunological areas, I saw a great opportunity to gain an extended understanding of ALK’s research and establish a unique research profile for myself, combining clinical and translational aspects," Christian says.   

"I have gained valuable insights and the opportunity to work with top-class experts within the field of respiratory allergies, building bridges between the clinic, academia and industry. There is a high level of motivation and dedication here – both towards helping people living with allergy and also to support each other as colleagues. It is inspiring to be part of a workplace in which we all strive towards the same purpose, eager to deliver our very best whether working with high science or something else."  

#allergy #pharma #innovation #science #careers

We grant a pretty awesome research award at ALK! 🔬🏆 It’s called The Henning Løwenstein Research Award, and on 1 March 2024 it will once again be granted to a young scientist who has shown excellence within the field of allergy. 

In the beginning of the 1990s the award was first introduced as a recognition to Løwenstein and his scientific work that has been instrumental in the breakthrough facilitating ALK’s standardisation of allergen extracts in the 1970s.  

We are super excited about the event, and you’re invited to join it via our LinkedIn livestream! 🎥 Mark your calendar now, so you don’t miss out on this cool event featuring the highly recognised Professor Stephen Durham and Henning Løwenstein himself.
  
#research #allergy #pharma #innovation #HCP

ALK’s history goes more than a century back to when our pharma company was founded in 1923. Just like today, it can be tough being a startup, and it was not until January 1944, exactly 80 years ago, that our two founders were in a position to hire their first full-time manager to take care of the production and sale of our allergy preparations. It was a huge and important step in the development of ALK. The new employee was a law student named Helle Olrik, who later became Managing Director of ALK.  

Today, our main focus is still to help people living with allergies. ALK now has 2800 dedicated employees and is present in almost 50 countries.

#allergy #pharma #ALK100 #history #people

This time of year, when we experience freezing temperatures and spend most of our time indoors to stay warm, is the ideal indoor climate for house dust mites. 

The microscopic eight-legged creatures thrive in warm and humid environments, especially in our beds, and mainly feed on our dead skin-cells. They can be found in abundance in 90 % of homes all over the world. 

The allergens from house dust mites can trigger reactions ranging from itchy eyes, a runny nose, sneezing, coughing and feeling tired to more severe respiratory issues. If you experience such allergy symptoms during the winter, it might be relevant for you to reach out to your doctor to discuss potential symptom management options for you.  

#allergy #pharma #housedustmiteallergy #winterseason  

Sunday, 14 January 2024, was a historic day in the Kingdom of Denmark. HM Queen Margrethe II of Denmark abdicated after serving the country for 52 years, and her son, HM King Frederik X, is now sovereign of Denmark.  

At ALK, we wish to express our sincerest gratitude to HM Queen Margrethe II for being a tremendous representative for Denmark and a great support for the Danish business industry as well as an important ambassador for Danish life science companies in Denmark and abroad throughout her years on the throne.  

We also wish to congratulate HM King Frederik X on his succession to the throne and we wish HM King Frederik and HM Queen Mary of Denmark a bright future as the new royal couple. We look forward to the continued strong collaboration between the Danish business industry and The Royal House.  

#congratulations #allergy #pharma #KingdomofDenmark #lifescience #TheRoyalFamily 

ALK-

NET:ALK

ALK

Last Close

154.80

08/11 09:15

Market Cap

33.75B

Beta: -

Volume Today

40.49K

Avg: -